American Society of Clinical Psychopharmacology (ASCP)

Let's take a look at the next generation of pharmacotherapies for mood and anxiety disorders.

In this inaugural episode, experts discuss the limitations of current diagnosis-based frameworks in suicide research, emphasizing the need for more targeted interventions.

In the first ever episode of "Psychopharm Today," experts unpack why suicide needs its own research, how to design targeted studies, and what clinicians can do beyond diagnosis to reduce risk.

APA’s upcoming DSM shifts from “statistical” to “scientific,” adding dimensional, contextual, and biological factors to modernize diagnosis and address past critiques.

After FDA’s new warning, experts stress controlled data show acetaminophen in pregnancy isn’t tied to autism or ADHD; confounding fuels scares.

APA’s next DSM rebrands and adds context, cross-cutting symptoms, and biomarker-ready science to sharpen diagnoses and personalize psychiatric care.

New analysis finds postpartum depression and postpartum psychosis have distinct underlying biological mechanisms.

S. Nassir Ghaemi, MD, shares highlights from the ASCP task force consensus on psychiatric polypharmacy, emphasizing monotherapy and diagnostic reassessment.

ASPIRE survey reveals fatigue and cognitive impairment reduce work abilities and quality of life in narcolepsy and idiopathic hypersomnia, exposing unmet needs.

ASCP awardee Leslie Citrome explains why effect size, NNT, and NNH beat P-values, helping clinicians choose treatments tailored to each patient.

At the 2026 ASCP Annual Meeting, Eric Konofal, MD, PhD, argued that sleep assessment should become a routine part of ADHD evaluation and treatment.

Phase 3 data show COMP360 psilocybin rapidly lifts treatment-resistant depression, with durable MADRS gains and stronger effects from 2 sessions.

A phase 2b/3 trial of Forvisirvat in major depressive disorder is investigating potential sex-specific antidepressant effects in women.

Expert psychiatrists share new ASCP deprescribing guidance, tackling overprescribing, primary-care challenges, and practical tapering strategies to improve safer, patient-centered mental health care.

Clinicians explore transdiagnostic anhedonia—reward learning, loneliness, and digital rewards—offering practical ideas to personalize treatment.

New real-world data in obese, antidepressant-naive patients with MDD shows bupropion edging SSRIs on remission, though rates stay low.

Investigational depression drugs target SIRT6 epigenetics, histamine H3, and AMPA.

The ASCp meeting spotlights a fast-acting psychedelic for postpartum depression, vasopressin-targeting drugs, and ketamine’s promise for Parkinson symptoms.

Researchers at the ASCP Annual Meeting reported on how impaired brain insulin signaling may predict worsening depression severity and the links between metabolism and mood.

ASCP 2026 leaders share practical ways to engage patients in acute psychosis—active listening, noncollusive language, and rapport before assessment.

AI adoption in psychiatry and emerging psychedelic therapies are among the most anticipated topics at ASCP 2026, according to Benjamin Brody, MD.

David W. Goodman, MD, discusses the new ASCP consensus recommendations on when clinicians should consider deprescribing stimulants as part of good ADHD care.

John J. Miller, MD, Psychiatric Times editor in chief, looks forward to learning and sharing the late-breaking science, expert interviews, and new podcast conversations in psychopharmacology.

Explore practical ways psychiatrists address sexual side effects and adjust medication for older adults.

Learn more about strategies for deprescribing, and the importance of finding the most effective medication possible.

HHS targets psychiatric overprescribing; expert Joseph F. Goldberg, MD, urges careful deprescribing—stop ineffective medications and replace with evidence-based treatments.

HHS targets “psychiatric overprescribing,” but experts urge thoughtful deprescribing—stopping ineffective medications while replacing them with evidence-based alternatives tailored to patients.

New expert guidance shows how to safely review and taper psychiatric medications, weighing efficacy, risks, interactions, and patient input in mood disorders.

Discover promising new treatments for schizophrenia, including NBI-1117568 and CPL’36, showcasing significant symptom improvements and safety profiles.